Research and laboratory use only. Not for human consumption.
Epitalon
Epitalon, also known as Epithalon or Epithalone, is a four-amino-acid peptide with the sequence Ala-Glu-Asp-Gly (AEDG). It originated from research into pineal peptide preparations and has subsequently been investigated in areas including neuroendocrine signalling, melatonin regulation, cellular ageing and telomere biology.
What is Epitalon?
Epitalon is a short peptide consisting of four amino acids: alanine, glutamic acid, aspartic acid and glycine . Its amino-acid sequence is therefore abbreviated AEDG.
The peptide was developed through research into pineal-gland peptide preparations, particularly a preparation known as Epithalamin.
Researchers identified the AEDG sequence while investigating whether short peptide sequences could reproduce selected biological activities associated with the larger pineal extract.
Epitalon subsequently attracted attention because laboratory and animal studies reported effects involving melatonin, circadian biology, gene expression, antioxidant processes, cellular ageing and telomerase.
However, considerable uncertainty remains regarding which mechanisms are biologically important, how findings translate to humans and whether observed laboratory effects have therapeutic significance.
Why is it called Epitalon?
Unlike abbreviations such as BPC-157, Epitalon is not generally treated as an acronym with a standardized literal expansion.
The name developed from the scientific programme surrounding Epithalamin, a peptide preparation obtained from bovine pineal tissue.
Epitalon was synthesized based on the amino-acid composition identified during this work and consists of only four residues.
The literature also uses several spelling variants, including Epithalon, Epithalone and Epitalone. The structural identifier AEDG is therefore often useful because it directly describes the amino-acid sequence.
Epitalon and Epithalamin are not the same material
Older longevity and pineal-gland literature sometimes discusses Epithalamin alongside Epitalon. The results should not automatically be combined because one is a peptide mixture and the other is a defined four-residue peptide.
Epitalon
A defined tetrapeptide consisting of alanine, glutamic acid, aspartic acid and glycine.
Its molecular identity can therefore be specified precisely.
Epithalamin
Epithalamin was developed as a complex peptide preparation derived from bovine pineal tissue.
Some older human ageing and melatonin studies used Epithalamin rather than purified Epitalon.
Those results should therefore not automatically be attributed to AEDG.
A human study using Epithalamin does not necessarily demonstrate that isolated Epitalon produces the same biological effect. ASA Research distinguishes the two wherever the underlying study allows.
Amino-acid sequence & molecular characteristics
Epitalon is substantially smaller than many research peptides. Its four-residue structure gives it a molecular weight of approximately 390.35 g/mol in the free-base form.
Why are researchers interested in Epitalon?
Interest in Epitalon comes from several distinct areas of experimental biology rather than one established therapeutic mechanism.
Circadian Biology
Pineal-gland research has investigated Epitalon's relationship with melatonin production and genes involved in circadian rhythm regulation.
Telomere Biology
Human cell-culture studies reported telomerase activation and changes in telomere length following exposure to Epitalon.
Retinal Biology
Pineal and retinal tissues share developmental and neuroendocrine features, and retinal models have formed part of Epitalon research.
Geroscience
Animal lifespan experiments, cellular senescence research and neuroendocrine ageing studies have contributed to Epitalon's reputation as a geroscience research compound.
How might Epitalon influence biological systems?
Epitalon does not have one clinically validated mechanism of action. Laboratory studies instead suggest several possible molecular pathways.
Telomerase Activity
Human somatic-cell experiments reported expression of the telomerase catalytic subunit, increased telomerase activity and telomere elongation.
Melatonin Signalling
Pineal research has examined whether AEDG influences melatonin synthesis and neuroendocrine circadian regulation.
Gene Regulation
Experimental studies have reported changes in gene expression, including circadian genes and other regulatory pathways.
Cellular Protection
Antioxidant, antimutagenic and neuroprotective effects have been proposed in experimental systems, although their clinical importance remains uncertain.
Epitalon and telomerase
One of the most widely discussed areas of Epitalon research concerns telomerase, the enzyme capable of adding DNA repeats to telomere ends.
Experiments using human somatic cells reported that Epitalon induced expression of the catalytic telomerase subunit and increased measurable telomerase activity.
Subsequent experiments with ageing human fibroblast cultures reported telomere elongation and increased proliferative potential following peptide exposure.
These are important cell-culture findings, but they do not establish that Epitalon slows human ageing, extends human lifespan or produces safe systemic telomere elongation in people.
Telomerase biology is also complex because telomerase activity is characteristic of many malignant cells. Increasing telomerase activity cannot therefore be assumed to be universally beneficial.
What might Epitalon eventually be investigated for?
The areas below are possible directions suggested by experimental research. They are not approved uses and should not be interpreted as treatment claims.
Circadian Rhythm Disorders
Effects on melatonin-associated biology and circadian genes have led to interest in whether pineal peptides could eventually contribute to research into disrupted sleep-wake and circadian physiology. Human therapeutic efficacy is not established.
Retinal Degeneration
Experimental and small clinical reports involving retinal degeneration have generated interest in retinal and neuroprotective applications. The evidence is not sufficient to establish Epitalon as an ophthalmic treatment.
Geroscience & Cellular Ageing
Telomerase, telomere biology, oxidative stress and neuroendocrine ageing make Epitalon scientifically interesting within geroscience. There is no reliable evidence that it extends human lifespan.
Neuroendocrine Regulation
The pineal origin of the research programme and experimental effects on melatonin and circadian signalling have generated wider interest in neuroendocrine regulation.
Laboratory effects involving telomerase, melatonin or gene expression do not establish clinical safety or therapeutic efficacy in humans. Controlled clinical research would be required before any such use could be established.
How strong is the evidence?
Epitalon has a long experimental literature, but the evidence becomes substantially weaker when the question moves from molecular activity to proven therapeutic effects in humans.
Laboratory Evidence
Cell-culture and molecular studies have investigated telomerase, gene expression, enzyme activity and other biological effects.
Animal Evidence
Animal research has examined lifespan, melatonin secretion, retinal biology, neuroendocrine ageing and other endpoints.
Human Evidence
Human evidence is limited, frequently small or poorly characterized, and some older studies concern Epithalamin rather than purified Epitalon.
Established Medicine
Epitalon has not reached this stage and is not an FDA-approved drug or established therapeutic medicine.
What do we actually know in humans?
Human research is considerably less developed than the laboratory and animal evidence.
Human evidence concerning Epitalon itself remains limited and should be interpreted cautiously.
A study involving healthy women working night shifts examined the AEDG peptide in relation to a urinary melatonin metabolite and circadian-gene expression. FDA's subsequent review noted that the study evaluated biochemical endpoints rather than demonstrating a clinical therapeutic outcome.
Older Russian literature also describes retinal and ageing-related observations. However, some publications involve Epithalamin or do not clearly identify whether the material administered was Epitalon free base, a salt form or another pineal peptide preparation.
This creates significant uncertainty when attempting to define human efficacy, pharmacokinetics or safety for purified Epitalon.
Importantly, FDA reported in its current scientific evaluation that it had not identified adequate clinical safety data for Epitalon-related bulk drug substances administered to humans.
Where is Epitalon in the development process?
Despite a considerable experimental literature, Epitalon has not followed the conventional pharmaceutical development pathway through well-characterized Phase I, II and III programmes.
Investigational tetrapeptide
Current evidence does not establish Epitalon as an approved therapy for ageing, insomnia, retinal disease or any other medical condition.
What don't we know yet?
Factors affecting peptide stability
Epitalon may be supplied in different physical forms and salts. Stability information should therefore correspond to the precise material and analytical specification being studied rather than being generalized across all products described as “Epitalon.”
Temperature
Temperature can influence chemical degradation and long-term peptide stability.
Light
Exposure to light can contribute to degradation of susceptible laboratory materials.
Moisture
Moisture can affect physical properties and chemical stability of peptide preparations.
Chemical Form
Free-base and salt forms should be treated as analytically distinct materials when reviewing stability and characterization data.
Investigational — not an approved medicine
Epitalon remains an investigational research peptide. Neither Epitalon free base nor Epitalon acetate is a component of an FDA-approved drug.
Current evidence is insufficient to establish Epitalon as a safe or effective therapy for ageing, insomnia, retinal degeneration, circadian disorders or any other medical condition.
ASA Research Labs provides this information for scientific and educational purposes only. Nothing on this page should be interpreted as medical advice, clinical treatment guidance, dosing information or a recommendation for human use.
Selected scientific references
These papers provide scientific context for the molecular, pineal, telomerase, retinal and ageing research discussed in this profile. References are displayed without external website links.
Scientific research information only
This profile is provided for scientific and educational information. Epitalon is an investigational compound and is not presented by ASA Research Labs as an approved medicine, anti-ageing therapy, sleep treatment or treatment for retinal disease. Discussion of telomerase, telomeres, melatonin, animal lifespan studies, cellular experiments or potential applications does not establish safety or efficacy in humans. This information is not medical advice and does not provide instructions for administration, dosing or human use.